THC BioMed Announces Inclusion in the CSE Composite Index

Vancouver, British Columbia Jul 18, 2023 (Issuewire.com) – THC.CSE THCBF – OTC TFHD.F

THC BioMed Intl Ltd. (“THC BioMed” or the “Company”), a renowned innovator in the cannabis industry, is thrilled to announce its inclusion in the CSE Composite Index as of the market close on July 5, 2023.

The CSE Composite Index is administered by Solactive AG, a leading index provider serving 350 clients globally across Europe, America, and Asia. The index follows a set of robust policies and procedures, published on the CSE website, which are maintained by an Index Committee. This committee has the sole discretion to determine how policies and procedures are interpreted and can update them over time if deemed necessary.

“Our inclusion in the CSE Composite Index is a testament to our steady growth, financial performance, and commitment to our stakeholders,” says THC Biomed CEO John Miller. “We are honored to join the ranks of other esteemed companies on this index and are excited about the increased visibility and potential enhanced liquidity this development may bring.”

The inclusion in the CSE Composite Index marks a significant milestone for THC BioMed and serves as further recognition of the Company’s commitment to cultivating and supplying high-quality cannabis products for both the medical and recreational sectors.

For more information about THC BioMed’s business strategy, future, plans, and investment opportunities, please visit www.thcbiomed.com.

About THC BioMed

THC BioMed Intl Ltd. is a Cannabis Act Licensed Producer of medical and recreational cannabis. It is licensed to cultivate and sell dried, extract, edible, and topical cannabis. The Company is a pioneer in the cannabis industry, leading in scientific research and the development of products and services, with patient safety as a guiding principle.

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct.

Press Contact:

For additional information about THC BioMed’s product lines or to stay updated on the Company’s latest developments, visit www.thcbiomed.com.

For more information, media inquiries, or partnership opportunities, please contact:

President and CEO: John Miller

T: 1-844-THCMEDS

E: info@thcbiomed.com

About THC BioMed

THC BioMed Intl Ltd. is a Cannabis Act Licensed Producer of medical and recreational cannabis. It is licensed to cultivate and sell dried, extract, edible and topical cannabis. The Company is on the leading edge of scientific research and the development of products and services related in the medical cannabis industry. Patient safety is not merely a goal but a guiding principle for THC BioMed.

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. Forward-looking statements in this release include that the Company will continue to broaden its reach across the Canadian market. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.